File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The management of coronavirus infections with particular reference to SARS

TitleThe management of coronavirus infections with particular reference to SARS
Authors
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/
Citation
Journal Of Antimicrobial Chemotherapy, 2008, v. 62 n. 3, p. 437-441 How to Cite?
AbstractThe human coronaviruses (HCoV) OC43 and 229E are common causes of upper respiratory tract infections. Severe diseases were rare, however, until the emergence of the severe acute respiratory syndrome (SARS)-CoV in 2003. Since then, other novel CoV (NL63 and HKU1) have been described, and they have caused respiratory infections worldwide. Potentially exposed laboratory workers or animal handlers with rapidly progressive pneumonia not responding to standard antibacterial coverage must be isolated with contact and droplet, and for specific situations, airborne precautions, till rapid tests of respiratory and faecal samples are negative for SARS-CoV. Generally, the viral loads collected at different anatomical sites correlate with the severity of symptoms and mortality. Shedding of SARS-CoV peaks at day 10 after the onset of symptoms, which theoretically allows ample time for antiviral treatment. The disease is characterized by uncontrolled replication of the virus and a prominent pro-inflammatory response. No randomized controlled trials with a specific anti-coronavirus agent have been conducted with respect to therapy or prophylaxis. Reports using historical matched controls have suggested that treatment with interferon alfacon-1 (a synthetic interferon) combined with steroid, protease inhibitors together with ribavirin, or convalescent plasma containing neutralizing antibody, could be useful. Prophylaxis with interferon or hyperimmune globulin may be considered for unprotected exposure. The role of immunomodulators to decrease excessive inflammation remains elusive. Other non-SARS-CoV infections are generally milder in immunocompetent hosts, and scientific data on antiviral treatment of these viruses are scarce. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/157526
ISSN
2015 Impact Factor: 4.919
2015 SCImago Journal Rankings: 2.157
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, SSYen_US
dc.contributor.authorYuen, KYen_US
dc.date.accessioned2012-08-08T08:50:56Z-
dc.date.available2012-08-08T08:50:56Z-
dc.date.issued2008en_US
dc.identifier.citationJournal Of Antimicrobial Chemotherapy, 2008, v. 62 n. 3, p. 437-441en_US
dc.identifier.issn0305-7453en_US
dc.identifier.urihttp://hdl.handle.net/10722/157526-
dc.description.abstractThe human coronaviruses (HCoV) OC43 and 229E are common causes of upper respiratory tract infections. Severe diseases were rare, however, until the emergence of the severe acute respiratory syndrome (SARS)-CoV in 2003. Since then, other novel CoV (NL63 and HKU1) have been described, and they have caused respiratory infections worldwide. Potentially exposed laboratory workers or animal handlers with rapidly progressive pneumonia not responding to standard antibacterial coverage must be isolated with contact and droplet, and for specific situations, airborne precautions, till rapid tests of respiratory and faecal samples are negative for SARS-CoV. Generally, the viral loads collected at different anatomical sites correlate with the severity of symptoms and mortality. Shedding of SARS-CoV peaks at day 10 after the onset of symptoms, which theoretically allows ample time for antiviral treatment. The disease is characterized by uncontrolled replication of the virus and a prominent pro-inflammatory response. No randomized controlled trials with a specific anti-coronavirus agent have been conducted with respect to therapy or prophylaxis. Reports using historical matched controls have suggested that treatment with interferon alfacon-1 (a synthetic interferon) combined with steroid, protease inhibitors together with ribavirin, or convalescent plasma containing neutralizing antibody, could be useful. Prophylaxis with interferon or hyperimmune globulin may be considered for unprotected exposure. The role of immunomodulators to decrease excessive inflammation remains elusive. Other non-SARS-CoV infections are generally milder in immunocompetent hosts, and scientific data on antiviral treatment of these viruses are scarce. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/en_US
dc.relation.ispartofJournal of Antimicrobial Chemotherapyen_US
dc.subject.meshAnti-Inflammatory Agents - Therapeutic Useen_US
dc.subject.meshAntibodies, Viral - Therapeutic Useen_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Therapeutic Useen_US
dc.subject.meshInterferon-Alphaen_US
dc.subject.meshPatient Isolationen_US
dc.subject.meshRecombinant Proteinsen_US
dc.subject.meshRibavirin - Therapeutic Useen_US
dc.subject.meshSars Virus - Isolation & Purificationen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Diagnosis - Therapyen_US
dc.subject.meshSteroids - Therapeutic Useen_US
dc.titleThe management of coronavirus infections with particular reference to SARSen_US
dc.typeArticleen_US
dc.identifier.emailWong, SSY:samsonsy@hkucc.hku.hken_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.authorityWong, SSY=rp00395en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/jac/dkn243en_US
dc.identifier.pmid18565970-
dc.identifier.scopuseid_2-s2.0-49649123918en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-49649123918&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume62en_US
dc.identifier.issue3en_US
dc.identifier.spage437en_US
dc.identifier.epage441en_US
dc.identifier.eissn1460-2091-
dc.identifier.isiWOS:000258473200003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridWong, SSY=13310021400en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US
dc.identifier.citeulike3882762-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats